A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors ; volume:16 ; number:1 ; day:7 ; month:7 ; year:2016 ; pages:1-10 ; date:12.2016
BMC cancer ; 16, Heft 1 (7.7.2016), 1-10, 12.2016
- Urheber
-
Haense, N.
- Beteiligte Personen und Organisationen
-
Atmaca, A.
Pauligk, C.
Steinmetz, K.
Marmé, Frederik
Haag, G. M.
Rieger, M.
Ottmann, O. G.
Ruf, P.
Lindhofer, H.
Al-Batran, S.-E
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2449-0
- URN
-
urn:nbn:de:1111-2016071010591
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Haense, N.
- Atmaca, A.
- Pauligk, C.
- Steinmetz, K.
- Marmé, Frederik
- Haag, G. M.
- Rieger, M.
- Ottmann, O. G.
- Ruf, P.
- Lindhofer, H.
- Al-Batran, S.-E
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive factors in HER2-positive early breast cancer : endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival
Untersuchungen zur prognostischen Bedeutung und biologischen Funktion von NK-Zell-Rezeptor-Liganden im Serum und Tumorgewebe von Patientinnen mit zervikalen intraepithelialen Neoplasien (CIN I-III) und Zervixkarzinom
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
Anti-CD3 monoclonal antibody as a possible therapeutic alternative in HAM/TSP
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Anti-CD3 antibody treatment reduces scar formation in a rat model of myocardial infarction
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
Predictive factors in HER2-positive early breast cancer : endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival
Untersuchungen zur prognostischen Bedeutung und biologischen Funktion von NK-Zell-Rezeptor-Liganden im Serum und Tumorgewebe von Patientinnen mit zervikalen intraepithelialen Neoplasien (CIN I-III) und Zervixkarzinom
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
Anti-CD3 monoclonal antibody as a possible therapeutic alternative in HAM/TSP
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Anti-CD3 antibody treatment reduces scar formation in a rat model of myocardial infarction
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
Predictive factors in HER2-positive early breast cancer : endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival
Untersuchungen zur prognostischen Bedeutung und biologischen Funktion von NK-Zell-Rezeptor-Liganden im Serum und Tumorgewebe von Patientinnen mit zervikalen intraepithelialen Neoplasien (CIN I-III) und Zervixkarzinom
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
Anti-CD3 monoclonal antibody as a possible therapeutic alternative in HAM/TSP
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Anti-CD3 antibody treatment reduces scar formation in a rat model of myocardial infarction